[Discontinuation of immunosuppressive and immunomodulatory drugs in connective tissue diseases]
Clicks: 340
ID: 110968
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Popular Article
79.5
/100
336 views
271 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Remission in connective tissue diseases became a realistic goal of therapy nowadays. However, there is lack of recommendations on the management after achieving a remission. Chronic exposure to immunosuppressive or immunomodulatory drugs may be associated with adverse events, that is why temporal wi …
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (43 words).
Try re-searching for a better abstract.
| Reference Key |
b2015wiadomosci[discontinuation
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Targońska-Stępniak B;; |
| Journal | Wiadomosci lekarskie (Warsaw, Poland : 1960) |
| Year | 2015 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
National Center for Biotechnology Information
NCBI
NLM
MEDLINE
review
humans
pubmed abstract
nih
national institutes of health
national library of medicine
English Abstract
Bozena Targońska-Stepniak
pmid:26753211
Connective Tissue Diseases / drug therapy*
Drug Administration Schedule
Immunomodulation*
Immunosuppressive Agents / administration & dosage*
Immunosuppressive Agents / adverse effects
Recurrence
Remission Induction
Withholding Treatment*
|
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.